<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_synthetic" title="SL-BioDP: Multi-Cancer Interactive Tool for Prediction of Synthetic Lethality and Response to Cancer Treatment" shortTitle="synthetic" author="Xiang Deng, Shaoli Das, Kristin Valdez, Kevin Camphausen, Uma Shankavaram" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6694/11/11/1682/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
3.	LS	3.
Discussion	NN	discussion
</s>
</head>
<p>
<s type="decl">
Synthetic	JJ	Synthetic
lethality	NN	lethality
has	VBZ	have
immense	JJ	immense
potential	NN	potential
in	IN	in
cancer	NN	cancer
therapeutics	NNS	therapeutics
.	.	.
</s>
<s type="sub">
Where	WRB	where
the	DT	the
driver	NN	driver
genes	NNS	gene
or	CC	or
oncogenes	NNS	oncogen
cannot	MD	cannot
be	VB	be
targeted	VBN	target
,	,	,
synthetic	JJ	synthetic
lethal	JJ	lethal
interactors	NNS	interactor
can	MD	can
potentially	RB	potentially
serve	VB	serve
as	IN	as
drug	NN	drug
targets	NNS	target
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
mutations	NNS	mutation
in	IN	in
the	DT	the
driver	NN	driver
genes	NNS	gene
,	,	,
as	IN	as
the	DT	the
mutant	JJ	mutant
tumor	NN	tumor
cells	NNS	cell
are	VBP	be
dependent	JJ	dependent
upon	IN	upon
the	DT	the
synthetic	JJ	synthetic
lethal	JJ	lethal
interactors	NNS	interactor
for	IN	for
their	PRP$	their
survival	NN	survival
.	.	.
</s>
<s type="decl">
Recent	JJ	Recent
advances	NNS	advance
in	IN	in
RNAi	NNP	RNAi
and	CC	and
CRISPR	NNP	CRISPR
technologies	NNS	technology
have	VBP	have
enabled	VBN	enable
large-scale	JJ	large-scale
synthetic	JJ	synthetic
lethality	NN	lethality
screens	NNS	screen
for	IN	for
individual	JJ	individual
genes	NNS	gene
to	TO	to
be	VB	be
performed	VBN	perform
in	IN	in
human	JJ	human
cell	NN	cell
lines	NNS	line
.	.	.
</s>
<s type="decl">
The	DT	the
genetic	JJ	genetic
dependency	NN	dependency
map	NN	map
(	-LRB-	(
DepMap	NNP	DepMap
)	-RRB-	)
project	NN	project
is	VBZ	be
dedicated	VBN	dedicate
towards	IN	towards
finding	VBG	find
genetic	JJ	genetic
dependencies	NNS	dependency
from	IN	from
the	DT	the
published	VBN	publish
shRNA/CRISPR	NN	shRNA/CRISPR
or	CC	or
drug	NN	drug
screening	NN	screening
data	NNS	datum
in	IN	in
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
.	.	.
</s>
<s type="decl">
While	IN	while
identifying	VBG	identify
genetic	JJ	genetic
dependencies	NNS	dependency
or	CC	or
essentiality	NN	essentiality
in	IN	in
the	DT	the
context	NN	context
of	IN	of
specific	JJ	specific
genetic	JJ	genetic
alterations	NNS	alteration
is	VBZ	be
important	JJ	important
for	IN	for
screening	VBG	screen
potential	JJ	potential
targets	NNS	target
for	IN	for
cancer	NN	cancer
therapy	NN	therapy
,	,	,
identification	NN	identification
of	IN	of
clinically	RB	clinically
relevant	JJ	relevant
synthetic	JJ	synthetic
lethal	JJ	lethal
pairs	NNS	pair
in	IN	in
cancers	NNS	cancer
has	VBZ	have
been	VBN	be
a	DT	a
challenge	NN	challenge
.	.	.
</s>
<s type="decl">
A	DT	a
recent	JJ	recent
work	NN	work
tried	VBD	try
to	TO	to
address	VB	address
this	DT	this
limitation	NN	limitation
with	IN	with
an	DT	a
in	IN	in
silico	NN	silico
analysis	NN	analysis
of	IN	of
clinical	JJ	clinical
relevance	NN	relevance
of	IN	of
the	DT	the
SL	NN	SL
interactions	NNS	interaction
identified	VBN	identify
from	IN	from
in	RB	in
vitro	NN	vitro
SL	NN	SL
screens	NNS	screen
and	CC	and
reported	VBD	report
that	IN	that
only	RB	only
a	DT	a
fraction	NN	fraction
of	IN	of
these	DT	this
SL	NN	SL
interactions	NNS	interaction
hold	VBP	hold
up	RP	up
to	TO	to
be	VB	be
clinically	RB	clinically
significant	JJ	significant
when	WRB	when
tested	VBN	test
on	IN	on
TCGA	NNP	TCGA
tumor	NN	tumor
data	NNS	datum
.	.	.
</s>
<s type="decl">
Also	RB	also
,	,	,
these	DT	this
in	IN	in
vitro	NN	vitro
screens	NNS	screen
are	VBP	be
costly	JJ	costly
and	CC	and
finding	VBG	find
synthetic	JJ	synthetic
lethal	JJ	lethal
interactors	NNS	interactor
for	IN	for
many	JJ	many
cancer	NN	cancer
genes	NNS	gene
remain	VBP	remain
challenging	JJ	challenging
.	.	.
</s>
<s type="decl">
SL-BioDP	NNP	SL-BioDP
addresses	VBZ	address
such	JJ	such
problems	NNS	problem
by	IN	by
using	VBG	use
a	DT	a
computational	JJ	computational
method	NN	method
that	WDT	that
leverages	VBZ	leverage
the	DT	the
available	JJ	available
cancer	NN	cancer
genetic	JJ	genetic
data	NNS	datum
resources	NNS	resource
to	TO	to
predict	VB	predict
synthetic	JJ	synthetic
lethal	JJ	lethal
partners	NNS	partner
of	IN	of
all	DT	all
cancer	NN	cancer
susceptibility	NN	susceptibility
genes	NNS	gene
and	CC	and
assesses	VBZ	assess
the	DT	the
clinical	JJ	clinical
relevance	NN	relevance
from	IN	from
matched	VBN	match
clinical	JJ	clinical
data	NNS	datum
.	.	.
</s>
<s type="decl">
The	DT	the
computational	JJ	computational
predictions	NNS	prediction
of	IN	of
SL	NN	SL
interactions	NNS	interaction
were	VBD	be
subjected	VBN	subject
to	IN	to
extensive	JJ	extensive
in	IN	in
silico	NN	silico
validation	NN	validation
using	VBG	use
either	CC	either
published	VBN	publish
literature	NN	literature
or	CC	or
shRNA	NN	shRNA
and	CC	and
drug	NN	drug
screening	NN	screening
data	NNS	datum
from	IN	from
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
.	.	.
</s>
<s type="decl">
SL-BioDP	NNP	SL-BioDP
is	VBZ	be
a	DT	a
comprehensive	JJ	comprehensive
resource	NN	resource
for	IN	for
the	DT	the
query	NN	query
and	CC	and
visualization	NN	visualization
of	IN	of
cancer-specific	JJ	cancer-specific
synthetic	JJ	synthetic
lethality	NN	lethality
and	CC	and
potential	JJ	potential
drug	NN	drug
targets	NNS	target
based	VBN	base
on	IN	on
the	DT	the
concept	NN	concept
of	IN	of
synthetic	JJ	synthetic
lethality	NN	lethality
.	.	.
</s>
<s type="decl">
The	DT	the
utility	NN	utility
of	IN	of
this	DT	this
web	NN	web
tool	NN	tool
is	VBZ	be
that	IN	that
it	PRP	it
enables	VBZ	enable
multilevel	JJ	multilevel
querying	NN	querying
based	VBN	base
on	IN	on
cancer	NN	cancer
genes	NNS	gene
,	,	,
tissues	NNS	tissue
,	,	,
or	CC	or
drugs	NNS	drug
of	IN	of
interest	NN	interest
.	.	.
</s>
<s type="decl">
In	IN	in
contrast	NN	contrast
to	IN	to
the	DT	the
other	JJ	other
database	NN	database
resources	NNS	resource
on	IN	on
synthetic	JJ	synthetic
lethality	NN	lethality
,	,	,
SL-BioDP	NNP	SL-BioDP
enables	VBZ	enable
assessment	NN	assessment
of	IN	of
the	DT	the
clinical	JJ	clinical
relevance	NN	relevance
of	IN	of
targeting	VBG	target
the	DT	the
SL	NN	SL
interactor	NN	interactor
gene	NN	gene
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
mutation	NN	mutation
in	IN	in
the	DT	the
primary	JJ	primary
gene	NN	gene
.	.	.
</s>
<s type="decl">
The	DT	the
prediction	NN	prediction
of	IN	of
drug	NN	drug
response	NN	response
depending	VBG	depend
on	IN	on
the	DT	the
presence	NN	presence
of	IN	of
mutations	NNS	mutation
in	IN	in
the	DT	the
primary	JJ	primary
genes	NNS	gene
is	VBZ	be
another	DT	another
important	JJ	important
feature	NN	feature
added	VBN	add
in	IN	in
SL-BioDP	NNP	SL-BioDP
.	.	.
</s>
<s type="decl">
Our	PRP$	our
analysis	NN	analysis
of	IN	of
published	VBN	publish
drug	NN	drug
screening	NN	screening
data	NNS	datum
and	CC	and
gene	NN	gene
mutation	NN	mutation
data	NNS	datum
from	IN	from
matched	VBN	match
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
identified	VBD	identify
known	VBN	know
synthetic	JJ	synthetic
lethality-based	JJ	lethality-based
drug	NN	drug
targets	NNS	target
like	IN	like
sensitivity	NN	sensitivity
of	IN	of
the	DT	the
drug	NN	drug
,	,	,
olaparib	NN	olaparib
(	-LRB-	(
PARP	NNP	PARP
inhibitor	NN	inhibitor
)	-RRB-	)
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
mutation	NN	mutation
in	IN	in
the	DT	the
<hi rend="italic">
BRCA1	NNP	BRCA1
</hi>
gene	NN	gene
,	,	,
and	CC	and
in	IN	in
general	JJ	general
the	DT	the
homologous	JJ	homologous
recombination	NN	recombination
repair	NN	repair
pathway	NN	pathway
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
analysis	NN	analysis
offers	VBZ	offer
to	TO	to
look	VB	look
into	IN	into
new	JJ	new
potentially	RB	potentially
effective	JJ	effective
gene	NN	gene
mutation-based	JJ	mutation-based
drug	NN	drug
therapies	NNS	therapy
.	.	.
</s>
<s type="decl">
We	PRP	we
extended	VBD	extend
our	PRP$	our
analysis	NN	analysis
to	TO	to
infer	VB	infer
potential	JJ	potential
synergy	NN	synergy
between	IN	between
drugs	NNS	drug
targeting	VBG	target
the	DT	the
predicted	VBN	predict
SL	NN	SL
interactors	NNS	interactor
.	.	.
</s>
<s type="decl">
We	PRP	we
reasoned	VBD	reason
that	IN	that
if	IN	if
the	DT	the
presence	NN	presence
of	IN	of
a	DT	a
mutation	NN	mutation
(	-LRB-	(
or	CC	or
loss	NN	loss
of	IN	of
function	NN	function
)	-RRB-	)
in	IN	in
a	DT	a
primary	JJ	primary
gene	NN	gene
makes	VBZ	make
cancer	NN	cancer
cells	NNS	cell
sensitive	JJ	sensitive
to	IN	to
certain	JJ	certain
drugs	NNS	drug
targeting	VBG	target
an	DT	a
SL	NN	SL
interactor	NN	interactor
,	,	,
then	RB	then
it	PRP	it
is	VBZ	be
highly	RB	highly
likely	JJ	likely
that	IN	that
the	DT	the
drugs	NNS	drug
targeting	VBG	target
the	DT	the
primary	JJ	primary
gene	NN	gene
will	MD	will
also	RB	also
make	VB	make
the	DT	the
cancer	NN	cancer
cells	NNS	cell
sensitive	JJ	sensitive
to	IN	to
those	DT	this
drugs	NNS	drug
targeting	VBG	target
the	DT	the
SL	NN	SL
interactor	NN	interactor
.	.	.
</s>
<s type="decl">
These	DT	this
inferred	VBN	infer
drug	NN	drug
synergies	NNS	synergy
can	MD	can
be	VB	be
searched	VBN	search
in	IN	in
SL-BioDP	NNP	SL-BioDP
for	IN	for
each	DT	each
of	IN	of
the	DT	the
18	CD	18
tumor	NN	tumor
histologies	NNS	histology
included	VBN	include
in	IN	in
SL-BioDP	NNP	SL-BioDP
.	.	.
</s>
<s type="decl">
In	IN	in
support	NN	support
of	IN	of
our	PRP$	our
predictions	NNS	prediction
of	IN	of
synergistic	JJ	synergistic
drugs	NNS	drug
in	IN	in
cancers	NNS	cancer
,	,	,
we	PRP	we
collected	VBD	collect
literature	NN	literature
references	NNS	reference
and	CC	and
reports	NNS	report
of	IN	of
ongoing	JJ	ongoing
clinical	JJ	clinical
trials	NNS	trial
,	,	,
which	WDT	which
is	VBZ	be
included	VBN	include
in	IN	in
Supplementary	NNP	Supplementary
Table	NNP	Table
S3	NNP	S3
.	.	.
</s>
<s type="decl">
Combined	VBN	Combine
together	RB	together
,	,	,
SL-BioDP	NNP	SL-BioDP
can	MD	can
serve	VB	serve
as	IN	as
a	DT	a
comprehensive	JJ	comprehensive
tool	NN	tool
,	,	,
for	IN	for
exploring	VBG	explore
potentially	RB	potentially
actionable	JJ	actionable
mutation-based	JJ	mutation-based
targeted	VBN	target
therapies	NNS	therapy
based	VBN	base
on	IN	on
the	DT	the
concept	NN	concept
of	IN	of
synthetic	JJ	synthetic
lethality	NN	lethality
,	,	,
that	WDT	that
shows	VBZ	show
possible	JJ	possible
clinical	JJ	clinical
relevance	NN	relevance
.	.	.
</s>
</p>
</text>